Use of palivizumab for prevention of hospitalization as a result of respiratory syncytial virus in infants with cystic fibrosis

Pediatric Infectious Disease Journal

Volumn 27, Issue 6, 2008, Pages 559-561

  Speer, Michael E ^a   Fernandes, Caraciolo J ^a   Boron, Marnie ^b   Groothuis, Jessie R ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MEDIMMUNE   (United States)

Author keywords

Cystic fibrosis; Hospitalization; Palivizumab; RSV

Indexed keywords

PALIVIZUMAB; TOBACCO SMOKE; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CHILD; CHRONIC LUNG DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; ENVIRONMENTAL EXPOSURE; FEMALE; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFANT; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE PREGNANCY; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; REGISTER; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RISK FACTOR; SCHOOL CHILD; VIRUS INFECTION; CHEMOPROPHYLAXIS; METHODOLOGY;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CHEMOPREVENTION; CYSTIC FIBROSIS; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 46249108292     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181673c15     Document Type: Article

References (12)

1. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr. 1988;113:826-830.
2. Armstrong D, Grimwood K, Carlin JB, et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol. 1998;26: 371-379.
3. Cunningham CK, McMillan, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks gestation. Pediatrics. 1990;88: 527-532.
4. Groothuis JR, Guiterrez KM, Lauer BA. Respiratory syncytial virus in children with bronchopulmonary dysplasia. Pediatrics. 1988;82:199-203.
5. AAP (American Academy of Pediatrics). Respiratory syncytial virus. In: Pickering LK, ed. Red Book. 27th ed. Report of the committee on infectious diseases. Elk Grove Village, IL: American Academy of Pediatrics. 2006:560 -567.
6. Palivizumab Outcomes Registry Study Group. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from the Palivizumab Outcomes Registry. Pediatr Pulmonol. 2003;35:484-489.
7. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J. 2003;22:S46 -S54.
8. Gelfand A, Cohen A, Boron M, Rankin M. The Synagis Outcomes Registry Group. RSV prophylaxis in 60 children with cystic fibrosis; results from the 'Real World' Experience-Palivizumab Outcomes Registry 2000-2003. Paper presented at: 2004 American Thoracic Society International Conference; May 21-26; Orlando, FL. Poster D44.
9. Speer ME, Fernandes CJ. Palivizumab prophylaxis in infants with cystic fibrosis. Paper presented at: 2006 Pediatric Academic Societies Meetings; May 2006; San Francisco, CA. Abstract 5530.172.
10. Speer ME, Fernandes CJ. Palivizumab prophylaxis in infants with cystic fibrosis. Paper presented at: 2006 American Academy of Pediatrics National Conference and Exhibition; October 6-8, 2006; Atlanta, GA. Abstract 837.
11. GraphPad Software, Inc. 5755 Oberlin Drive #110. San Diego, CA 92121 USA.
12. Cohen AH, Boron ML, Dingivan C. A phase IV study of the safety of synagis (Palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis. Paper presented at: International onference of the American Thoracic Society; May 20-25, 2005; San iego, CA. Abstract-A53.